Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.60 |
| ▸ | ALB | P02768 | 2/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.44 |
| ▸ | GNPAT | O15228 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GLP1R | P43220 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25542854 | 0.92 | FOLH1 (0.58) | FOLH1ALBNOD1EPHX2GLP1R | |
| SCHEMBL29617648 | 0.92 | NOD1 (0.51) | FOLH1ALBNOD1GNPATEPHX2 | |
| SCHEMBL20341086 | 0.82 | FOLH1 (0.70) | FOLH1ALBNOD1GNPATEPHX2 | |
| SCHEMBL24201118 | 0.82 | FOLH1 (0.70) | FOLH1 | |
| SCHEMBL25542887 | 0.81 | ALB (0.58) | FOLH1ALBNOD1EPHX2SMN1; SMN2 | |
| SCHEMBL7364390 | 0.81 | NOD1 (0.60) | NOD1GNPAT | |
| SCHEMBL13855520 | 0.81 | NOD1 (0.69) | FOLH1NOD1EPHX2GLP1R | |
| SCHEMBL21339757 | 0.81 | FOLH1 (0.57) | FOLH1GNPAT | |
| SCHEMBL16393150 | 0.80 | FOLH1 (0.71) | FOLH1ALBGNPATSMN1; SMN2 | |
| SCHEMBL1200060 | 0.80 | FOLH1 (0.71) | FOLH1ALBGNPATSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NSUN2, NSUN3, POLM | FOLH1 677/4885ALB 2473/4885NOD1 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.